Skip to content

Search

The END RHD CRE: Developing an end game for rheumatic heart disease in Australia

The END RHD CRE will undertake a number of projects across several disciplines of research including epidemiology, biomedical sciences; implementation and translation; and understanding the RHD community with a special focus on documenting the experiences of those living with the disease.

The NZ BPG Pharmacokinetics Study

This work will be undertaken in collaboration with The Kids Research Institute Australia and Australian based research teams to better understand how Penicillin works in Māori and Pacific children/teens who receive monthly BPG injections.

Working Towards a Better Understanding of ARF

Goal: Characterize the pattern of contemporary and endemic ARF and develop a biological signature to improve sensitivity and specificity of ARF diagnosis.

High risk of early sub-therapeutic penicillin concentrations after intramuscular benzathine penicillin G injections in Ethiopian children and adults with rheumatic heart disease

Intramuscular benzathine penicillin G (BPG) injections are a cornerstone of secondary prophylaxis to prevent acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Uncertainties regarding inter-ethnic and preparation variability, and target exposure profiles of BPG injection are key knowledge gaps for RHD control.

Primary prevention of acute rheumatic fever

Acute rheumatic fever (ARF) is an abnormal immune reaction following Streptococcus pyogenes (Strep A) infection of the throat, and likely the skin. Primary prevention is the prompt and appropriate antibiotic treatment of Strep A infection, and it can reduce the risk of developing ARF and subsequent rheumatic heart disease.

Disparity in Mortality From Rheumatic Heart Disease in Indigenous Australians

Indigenous Australians are much more likely to die from Rheumatic Heart Disease than other Australians.

Initiating an undiagnosed diseases program in the Western Australian public health system

We describe the initiation and summary outcomes of a public health system approach for complex undiagnosed patients- the Undiagnosed Diseases Program - WA

Clinical development strategy for a candidate group A streptococcal vaccine

This review outlines a clinical development strategy detailing the phases of development required for registration of a candidate Group A streptococci vaccin